4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

5.04 (USD) • At close January 15, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2023202220212020201920182017
Revenue 20.7233.12918.03813.6126.98614.135.79
Cost of Revenue 97.0963.883.0253.03838.71818.36213.573
Gross Profit -76.373-0.75115.018-39.426-31.732-4.232-7.783
Gross Profit Ratio -3.685-0.240.833-2.896-4.542-0.3-1.344
Reseach & Development Expenses 97.09680.25361.3653.03838.71818.36213.573
General & Administrative Expenses 36.49432.90828.01117.23813.8956.1673.489
Selling & Marketing Expenses 0000000
SG&A 36.49432.90828.01117.23813.8956.1673.489
Other Expenses 02.5380.016-0.181-0.046-0.002-0.04
Operating Expenses 133.59113.16189.37170.27652.61324.52917.062
Operating Income -112.867-110.032-71.333-56.664-50.764-10.399-11.272
Operating Income Ratio -5.446-35.165-3.955-4.163-7.267-0.736-1.947
Total Other Income Expenses Net 12.032.5380.016-0.0291.4580.8480.049
Income Before Tax -100.837-107.494-71.317-56.693-49.306-9.551-11.223
Income Before Tax Ratio -4.866-34.354-3.954-4.165-7.058-0.676-1.938
Income Tax Expense 0-6.418-3.02-0.1523.6330.848-0.089
Net Income -100.837-101.076-68.297-56.541-52.939-9.551-11.223
Net Income Ratio -4.866-32.303-3.786-4.154-7.578-0.676-1.938
EPS -2.58-3.12-2.46-2.12-2-0.76-0.76
EPS Diluted -2.58-3.12-2.46-2.12-2-0.76-0.76
EBITDA -107.118-106.152-68.313-55.221-44.623-9.702-10.646
EBITDA Ratio -5.169-35.165-3.955-4.057-5.652-0.687-1.839